Psychedelic Therapy Grounded in Mindfulness and Non-Duality

Psychedelic-assisted therapy is the fastest-moving frontier in mental health. The FDA has granted psilocybin “Breakthrough Therapy” designation. MDMA-assisted therapy for PTSD completed Phase III trials. Oregon has legalized guided psilocybin sessions. The science is no longer theoretical — it is clinical, regulatory, and accelerating.

But here is the question almost nobody in the psychedelic research community is asking with sufficient rigor: what is the role of contemplative practice — meditation, mindfulness, non-dual awareness — in making psychedelic therapy actually work?

This event brings together two people uniquely qualified to answer that question. Dr. Rael Cahn — Soul Syndicate's scientific advisor, director of the USC Center for Mindfulness Science, and Principal Investigator on the MAPS Phase III MDMA/PTSD epigenetic study — is joined by Dr. Michael Sapiro, an ordained Zen Buddhist monk, clinical psychologist, and psychedelic psychotherapist who authored Truth Medicine: Healing and Living Authentically Through Psychedelic Psychotherapy.

This is not a lecture. It is a dialogue between a neuroscientist who measures consciousness and a monk who embodies it — exploring what happens when those two traditions converge in a therapeutic setting.